—- Supercharging Research for the Cure, Crossing Valley of Death
AIM-HI Accelerator Fund is a cancer impact investment fund. AIM-HI is a new paradigm to fund translational research designed to focus on startups and research that have commercial potential at the early stage of cancer therapeutic discovery.
With an initial philanthropic investment from the National Foundation for Cancer Research (NFCR), AIM-HI’s mission is to accelerate the cancer drug discovery process and make it sustainable with the pharmaceutical industry for further development and then re-invest into the bench research process, for perpetuity.
AIM-HI seeks to pool immediately deployable funding to provide support for translating research into pharma-ready partnerships.
Our business model leverages how nonprofits, the pharmaceutical industry, researchers, entrepreneurs, patients, and their families can work together across the entire cancer care continuum — from prevention to diagnosis to treatment and ongoing care. By investing in promising early-stage startups in the diagnostic, biopharmaceutical and medical technology sectors, AIM-HI’s vision is to help them cross the “Valley of Death” and produce more targeted and effective therapeutics for cancer patients worldwide.